Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR3 N540K |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR3 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR3 N540K | Advanced Solid Tumor | resistant | FGFR3 Inhibitor | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226). | 26992226 |
FGFR3 N540K | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinicl study, Balversa (erdafitinib) inhibited proliferation of transformed cells expressing FGFR3 N540K in culture (PMID: 26992226). | 26992226 |
FGFR3 N540K | Advanced Solid Tumor | resistant | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to Truseltiq (infigratinib) in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | decreased response | FGFR3 Inhibitor | Zoligratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | decreased response | FGFR Inhibitor (Pan) | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880). | 28034880 |
FGFR3 N540K | Advanced Solid Tumor | decreased response | FGFR Inhibitor (Pan) | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880). | 28034880 |